Quote:

---

CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension.

---

Is that the clue to the label extension? What is a registration-directed study? Rolling in patients from the previous study, so its shortening the trial dramatically? Someone explain that please to me.

This is a great day, all the best to our patients!